Mydayis ER Capsules Dosage

Generic name: DEXTROAMPHETAMINE SULFATE 3.125mg, DEXTROAMPHETAMINE SACCHARATE 3.125mg, AMPHETAMINE ASPARTATE MONOHYDRATE 3.125mg, AMPHETAMINE SULFATE 3.125mg
Dosage form: capsule, extended release
Drug class: CNS stimulants

Medically reviewed by Drugs.com. Last updated on Mar 10, 2025.

Pretreatment Screening

Prior to treating patients with MYDAYIS, assess:

for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam)
the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating MYDAYIS

General Administration Information

Because the effects of MYDAYIS may last up to 16 hours and there is potential for insomnia, administer once daily in the morning upon awakening. In the event of a missed dose, do not administer later in the day. Do not administer additional medication to make up for the missed dose.

Administration Instructions

Administer MYDAYIS orally with or without food. Advise patients to take MYDAYIS consistently either with food or without food.

MYDAYIS may be administered in one of the following ways:

Swallow MYDAYIS capsules whole, or
Open capsule and sprinkle the entire contents over a spoonful of applesauce. The sprinkled applesauce should be consumed immediately; it should not be stored. Patients should take the sprinkled applesauce in its entirety without chewing.
The dose of a single capsule should not be divided.

Recommended Dosage

Adults (18 to 55 years)

The recommended starting dose of MYDAYIS is 12.5 mg once daily in the morning upon awakening. Initial doses of 25 mg once daily may be considered for some patients. Dosage may be adjusted in increments of 12.5 mg no sooner than weekly, up to a maximum dose of 50 mg once daily, based on the therapeutic needs and response of the patient. Doses above 50 mg daily have shown no additional clinically meaningful benefit.

Pediatric Patients (13 to 17 years)

The recommended starting dose is 12.5 mg once daily in the morning upon awakening. Dosage may be adjusted in increments of 12.5 mg no sooner than weekly, up to a recommended maximum dose of 25 mg once daily. The dose should be individualized according to the needs and response of the patient. Doses higher than 25 mg have not been evaluated in clinical trials in pediatric patients.

Dosage Modifications Due to Drug Interactions

Agents that alter gastrointestinal and urinary pH can impact urinary excretion and alter blood levels of amphetamine. Acidifying agents (e.g., ascorbic acid) decrease blood levels, while alkalinizing agents (e.g., sodium bicarbonate) increase blood levels. Adjust MYDAYIS dosage accordingly.

Dosage in Patients with Renal Impairment

In adult patients with severe renal impairment (GFR between 15 to <30 mL/min/1.73 m2), the recommended starting dose of MYDAYIS is 12.5 mg daily with a maximum recommended dose of 25 mg daily. MYDAYIS is not recommended for use in patients with end stage renal disease (ESRD <15 mL/min/1.73 m2). In pediatric patients (13 to 17 years) with severe renal impairment, the maximum dose is 12.5 mg, if tolerated.

Switching From Other Amphetamine Products

For patients switching from another medication or any other amphetamine products, discontinue that treatment, and titrate with MYDAYIS using the titration schedule.

Do not substitute for other amphetamine products on a milligram-per-milligram basis because of different amphetamine base compositions and differing pharmacokinetic profiles.